TGF-β downregulates CAIII expression via MAPK and PI3K signaling pathways in colon carcinoma and osteosarcoma cells
Keywords:CAIII, TGF-β, transcriptional regulation, colon carcinoma, osteosarcoma
- Anormal TGF-β expression is observed at different stages of colon carcinoma. Carbonic anhydrase III (CAIII) is involved in acute myeloid leukemia and hepatic carcinoma.
- TGF-β downregulated CAIII gene expression at the level of mRNA and protein in HT-29 colon cancer cells. TGF-β reduced the transcriptional activity of all CAIII promoter constructs, indicating that the potential response element for TGF-β-directed transcription factor is present within the -108/+86 region of the CAIII promoter. The same decreasing effect was observed in the Saos-2 osteosarcoma cell line.
- Our results show that the effect of TGF-β on CAIII is not tissue-specific.
Abstract: Identification of cancer-associated genes is critical for developing effective treatments of colorectal cancer (CRC). A limited number of studies have examined the mechanisms and genes underlying CRC. Abnormal transforming growth factor beta (TGF-β) expression was observed at different stages of carcinoma. We examined the effect of cancer-related cytokine TGF-β on carbonic anhydrase (CA) III gene expression in colon cancer HT-29 cells. TGF-β (500 U/mL) downregulated CAIII gene expression at both the mRNA and protein levels. Transient transfection experiments indicated that different CAIII promoter constructs were active in HT-29 cells. TGF-β reduced transcriptional activity of all promoter constructs, indicating that the potential response element for TGF-β-directed transcription lies within the -108/+86 region of the CAIII promoter. According to the non-Smad pathway inhibitory assay, TGF-β downregulated the CAIII gene through mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphoinositide-3-kinase (PI3K) pathways. The same decreasing effect was determined in the Saos-2, osteosarcoma cell line, indicating that the effect of TGF-β on CAIII was not tissue-specific. However, examination of PI3K and MAPK/ERK signaling pathways with suitable inhibitors revealed that the PI3K but not the MAPK/ERK pathway was responsible for TGF-β downregulation.
Received: October 8, 2018; Revised: February 26, 2019; Accepted: February 27, 2019; Published online: March 25, 2019
How to cite this article: Aydogan Turkoglu S, Okuyan D, Kockar K. TGF-β
downregulates CAIII expression via MAPK and PI3K signaling pathways in colon carcinoma and osteosarcoma cells. Arch Biol Sci. 2019;71(3):393-401.
Balch C, Ramapuram JB, Tiwari AK. The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. Front Pharmacol. 2017;8:267.
Markowitz SD, Bertagnolli MM. Molecular origins of cancer:molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449-60.
Vogelstein B, Kinzler KW. The path to cancer–three strikes and you’re out. N Engl J Med. 2015;373(20):1895-8.
Wang TL, Rago C, Silliman N, Ptak J, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci U S A. 2002;99(5):3076-80.
Rodriguez-Paredes M. and Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330-9.
Jung B, Staudacher JJ, Beauchamp D. Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology. 2017;152(1):36-52.
Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC. Type III TGF-β Receptor Enhances Colon Cancer Cell Migration and Anchorage-Independent Growth. Neoplasia. 2011;13(8):758-70
Tian M and Schiemann WP.The TGF-β Paradox in Human Cancer: An Update. Future Oncol. 2009;5(2): 259-71.
Li F, Cao Y, Townsend CM Jr, Ko TC. TGF-b Signaling in Colon Cancer Cells. World J Surg. 2005;29(3):306-11.
Grady WM,and Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079-99
Dai HY, Hong CC, Liang SC, Yan MD, Lai GM, Cheng AL, Chuang SE. Carbonic Anhydrase III Promotes Transformation and Invasion Capability in Hepatoma Cells Through FAK Signaling Pathway. Mol Carcinog. 2008;47(12):956-63.
Roy P, Reavey E, Rayne M, Roy S, Abed El Baky M, Ishii Y, Bartholomew C. Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III. FEBS J. 2010;277(2):441-52.
Mohammad HK, Alzweiri MH, Khanfar MA, Al-Hiari YM. 6-Substituted nicotinic acid analogues, potent inhibitors of CAIII, used as therapeutic candidates in hyperlipidemia and cancer, Med Chem Res. 2017;26(7):1397-1404
Pinard MA, Mahon B, McKenna R. Probing the Surface of Human Carbonic Anhydrase for Clues towards the Design of Isoform Specific Inhibitors. Biomed Res Int. 2015;2015:453543.
Kivela AJ, Saarnio J, Karttunen TJ, Kivelä J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Rajaniemi H. Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci. 2001;46(10):2179-86
Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastoreková S, Pastorek J, Kairaluoma MI, Karttunen TJ. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol. 1998;153(1):279-85.
Niemelä AM, Hynninen P, Mecklin JP, Kuopio T, Kokko A, Aaltonen L, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Orntoft TF, Kruhøffer M, Haapasalo H, Parkkila S, Kivelä AJ. Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1760-6.
Kivelä A, Parkkila S, Saarnio J, Karttunen TJ, Kivelä J, Parkkila AK, Waheed A, Sly WS, Grubb JH, Shah G, Türeci O, Rajaniemi H. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol. 2000;156(2):577-84.
Kummola L, Hämäläinen JM, Kivelä J, Kivelä AJ, Saarnio J, Karttunen T, Parkkila S. Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer. 2005;18(5):41.
Viikilä P, Kivelä AJ, Mustonen H, Koskensalo S, Waheed A, Sly WS, Pastorek J, Pastorekova S, Parkkila S, Haglund C. Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas. World J Gastroenterol. 2016;22(36):8168-77.
Zhang J, Tsoi H, Li X, Wang H, Gao J, Wang K, Go MY, Ng SC, Chan FK, Sung JJ, Yu J. Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP–WT1–TBL1 axis. Gut. 2016;65(9):1482-93.
Kuo WH, Chiang WL, Yang SF, Yeh KT, Yeh CM, Hsieh YS, Chu SC. The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci. 2003;73(17):2211-23.
Türkoğlu S, Köçkar F. SP1 and USF differentially regulate ADAMTS1 gene expression under normoxic and hypoxic conditions in hepatoma cells. Gene. 2016;575(1):48-57.
Yıldırım H, Kockar F. TGF-b upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells. Cell Biol Int. 2009;33(9):1002-7
Tokay E, Kockar F. Identification of intracellular pathways through which TGF-β1 upregulates URG-4/URGCP gene expression in hepatoma cells. Life Sci. 2016;144:121-8.
Livak K.J, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.
Alper M, Kockar F. IL-6 upregulates a disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS-2) in human osteosarcoma cells mediated by JNK pathway. Mol Cell Biochem. 2014;393(1-2):165-75
Massagué J. TGFβ in Cancer. Cell. 2008;134(2):215-30
Zanetti D, Poli G, Vizio B, Zingaro B, Chiarpotto E, Biasi F. 4-Hydroxynonenal and transforming growth factor-b1 expression in colon cancer. Mol Aspects Med. 2003;24(4-5):273-80
Yang GZ, Hu L, Cai J, Chen HY, Zhang Y, Feng D, Qi CY, Zhai YX, Gong H, Fu H, Cai QP, Gao CF. Prognostic value of carbonic anhydrase II expression in colorectal carcinoma. BMC Cancer. 2015;15:209.
Mori M, Staniunas RJ, Barnard GF, Jessup JM, Steele Jr GD, Chen LB. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 1993;105(3):820-6
Bekku S, Mochizuki H, Yamamoto T, Ueno H, Takayama E, Tadakuma T. Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer. Hepatogastroenterology. 2000;47(34):998-1001.
Silagi ES, Batista P, Shapiro IM, Risbud MV. Expression of Carbonic Anhydrase III, a Nucleus Pulposus Phenotypic Marker, is Hypoxia-responsive and Confers Protection from Oxidative Stress-induced Cell Death. Scientific Reports. 2018;8:4856.
Zimmerman UJ, Wang P, Zhang X, Bogdanovich S, Forster R. Anti-Oxidative Response of Carbonic Anhydrase III in Skeletal Muscle. IUBMB Life. 2004;56(6):343-7.
Räisänen SR, Lehenkari P, Tasanen M, Rahkila P, Härkönen PL, Väänänen HK. Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis. Faseb J. 1999:13(3):513-22
Feng HZ, Jin JP. Carbonic Anhydrase III Is Expressed in Mouse Skeletal Muscles Independent of Fiber Type-Specific Myofilament Protein Isoforms and Plays a Role in Fatigue Resistance. Front Physiol. 2016;7:597.
Cabiscol E, Levine RL. The phosphatase activity of carbonic anhydrase III is reversibly regulated by glutathiolation. Proc Natl Acad Sci USA. 1996;93(9):4170-4
Chai YC, Jung CH, Lii CK, Ashraf SS, Hendrich S, Wolf B, Sies H, Thomas JA. Identification of an abundant S-thiolated rat liver protein as carbonic anhydrase III; characterization of S-thiolation and dethiolation reactions. Arch Biochem Biophys. 1991;284(2):270-8
Carter ND, Hewett-Emmett D, Jeffrey S, Tashian RE. Testosterone-induced, sulfonamide-resistant carbonic anhydrase isozyme of rat liver is indistinguishable from skeletal muscle carbonic anhydrase III. FEBS Lett. 1981;128(1):114-8.
Wistrand PJ. Carbonic anhydrase III in liver and muscle of male rats purification and properties. Ups J Med Sci. 2002;107(2):77-88.
Sanyal G, Swenson ER, Pessah NI, Maren TH. The carbon dioxide hydration activity of skeletal muscle carbonic anhydrase. Inhibition by sulfonamides and anions. Mol Pharmacol. 1982;22(1):211-20.
Lii CK, Chai YC, Zhao W, Thomas JA, Hendrich S. S-thiolation and irreversible oxidation of sulfhydryls on carbonic anhydrase III during oxidative stress: a method for studying protein modification in intact cells and tissues. Arch Biochem Biophys. 1994;308(1):231-9.
Thomas JA, Poland B, Honzatko R. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. Arch Biochem Biophys. 1995;319(1):1-9.
Yang R, Piperdi S, Zhang Y, Zhu Z, Neophytou N, Hoang BH, Mason G, Geller D, Dorfman H, Meyers PA, Healey JH, Phinney DG, Gorlick R. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res. 2016;474(1):178-89.
Park HY, Seo J, Bacchini P, Bertoni F, Park YK. Expression of Carbonic Anhydrase IX Correlates with Histologic Grade and Metastasis in Osteosarcoma. Korean J Pathol. 2010;44(4):384-9.
Wang TK, Lin YM, Lo CM, Tang CH, Teng CL, Chao WT, Wu MH, Liu CS, Hsieh M. Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells. Tumour Biol. 2016;37(6):7989-8005.
Liu RM, Desai LP. Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis. Redox Biol. 2015;6:565-77.